Vancouver, British Columbia – January 18, 2013 – Sirona Biochem Corp. (OTCQX: SRBCF, TSX-V: SBM, Frankfurt: ZSB), announced today its stock is now trading on OTCQX®, the highest OTC marketplace in the U.S., under the symbol SRBCF. Investors can find current financial disclosures and Real-Time Level 2 quotes for the Company on www.otcmarkets.com.
“The visibility and quality of the OTCQX market will help expand Sirona Biochem’s investor reach in the U.S.,” said Neil Belenkie, Chief Executive Officer of Sirona Biochem. “International interest in Sirona Biochem has increased and the OTCQX marketplace provides an accessible platform for U.S. investors to buy and trade our stock,” he added.
“OTCQX companies demonstrate their commitment to providing superior information to investors and maintaining the highest quality standards,” said R. Cromwell Coulson, President and Chief Executive Officer of OTC Markets Group. “We are pleased to welcome Sirona Biochem to OTCQX.”
Merriman Capital, Inc. will serve as Sirona Biochem’s Principal American Liaison (“PAL”) on OTCQX, responsible for providing guidance on OTCQX requirements.
OTC Markets Group Inc. (OTCQX: OTCM) operates the world’s largest Open, Transparent and Connected financial marketplace platform, delivering price transparency in almost 10,000 OTC securities. The OTC Link® ATS directly links broker-dealers that provide liquidity and execution services. We organize the wide spectrum of OTC-traded securities into three marketplaces to inform investors of opportunities and risks – OTCQX® – The Intelligent Marketplace for the Best OTC Companies; OTCQB® – The Venture Marketplace; and OTC Pink® – The Open Marketplace. Our financial marketplace platform enables smarter trading through any broker at the best possible price, and empowers companies to improve the quality and availability of information for their investors. To learn more about our Open, Transparent and Connected financial marketplaces, visit www.otcmarkets.com.
About Sirona Biochem Corp.
Sirona Biochem is a biotechnology company developing diabetes therapeutics, skin depigmenting and anti-aging agents for cosmetic use, biological ingredients and cancer vaccine antigens. The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules. For more information visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, contact:
Sirona Biochem Corp.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.